Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Johnsson

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Advances in Experimental Medicine and Biology|July 12, 2011
Internal simulation of perceptions and actionsMagnus Johnsson, David Gil
Lakartidningen|November 7, 2023
Staffan Svensson, Magnus Johnsson
Lakartidningen|February 11, 2022
[Cervical myelopathy due to nitrous oxide inhalation]Staffan Svensson, Allan Karbassi, Magnus Johnsson
Heliyon|January 1, 2024
Clinical stage and plasma neurofilament concentration in adults with Friedreich ataxiaMagnus Johnsson, Henrik Zetterberg, Kaj Blennow, et al.
Neural Networks : the Official Journal of the International Neural Network Society|March 6, 2012
Using GNG to improve 3D feature extraction--application to 6DoF egomotionDiego Viejo, Jose Garcia, Miguel Cazorla, et al.
Sensors (Basel, Switzerland)|June 9, 2018
Collaborative Working Architecture for IoT-Based ApplicationsHiginio Mora, María Teresa Signes-Pont, David Gil, et al.
Multiple Sclerosis and Related Disorders|April 2, 2026
Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosisMagnus Johnsson, Jan Lycke, Lenka Novakova, et al.
Biology of Reproduction|March 1, 2013
Semen parameters can be predicted from environmental factors and lifestyle using artificial intelligence methodsJose L Girela, David Gil, Magnus Johnsson, et al.
Annals of Clinical and Translational Neurology|June 17, 2022
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorderMagnus Johnsson, Fredrik Asztely, Susanne Hejnebo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 20, 2022
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumabMagnus Johnsson, Helen H Farman, Kaj Blennow, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|July 12, 2011
Internal simulation of perceptions and actionsMagnus Johnsson, David Gil
Lakartidningen|November 7, 2023
Staffan Svensson, Magnus Johnsson
Lakartidningen|February 11, 2022
[Cervical myelopathy due to nitrous oxide inhalation]Staffan Svensson, Allan Karbassi, Magnus Johnsson
Heliyon|January 1, 2024
Clinical stage and plasma neurofilament concentration in adults with Friedreich ataxiaMagnus Johnsson, Henrik Zetterberg, Kaj Blennow, et al.
Neural Networks : the Official Journal of the International Neural Network Society|March 6, 2012
Using GNG to improve 3D feature extraction--application to 6DoF egomotionDiego Viejo, Jose Garcia, Miguel Cazorla, et al.
Sensors (Basel, Switzerland)|June 9, 2018
Collaborative Working Architecture for IoT-Based ApplicationsHiginio Mora, María Teresa Signes-Pont, David Gil, et al.
Multiple Sclerosis and Related Disorders|April 2, 2026
Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosisMagnus Johnsson, Jan Lycke, Lenka Novakova, et al.
Biology of Reproduction|March 1, 2013
Semen parameters can be predicted from environmental factors and lifestyle using artificial intelligence methodsJose L Girela, David Gil, Magnus Johnsson, et al.
Annals of Clinical and Translational Neurology|June 17, 2022
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorderMagnus Johnsson, Fredrik Asztely, Susanne Hejnebo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 20, 2022
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumabMagnus Johnsson, Helen H Farman, Kaj Blennow, et al.
Pageof 2